Jaroslaw T. Hepel Assistant Professor of Radiation Oncology, Assistant Professor of Neurosurgery

Jaroslaw T. Hepel, MD, serves as director of the Rhode Island Hospital stereotactic radiotherapy and radiosurgery program and as an assistant professor in the department of radiation oncology at The Warren Alpert Medical School of Brown University. He also serves as adjunct assistant professor at Tufts University and as associate director of the Tufts-Affiliated Hospitals Residency Training Program in Radiation Oncology. He is board certified in radiation oncology by the American Board of Radiology and in internal medicine by the American Board of Internal Medicine.

Dr. Hepel received his undergraduate degree at Cornell University in 1997 with distinction in all subjects. He earned his medical degree at the University of Rochester in 2001, and then completed an internal medicine residency at the University of California Irvine Medical Center. He then went on to complete residency in the specialty of radiation oncology at Tufts Medical Center in Boston, MA.

Dr. Hepel has broad experience and knowledge, and is active in caring for patients with a wide range of malignant diseases. However, he holds a particular interest and clinical expertise in the treatment of breast cancer and in stereotactic radiosurgery/radiotherapy for diseases involving the brain, spine, lung, liver and other sites. He is not only very active in the clinic but also has a keen academic interest in these areas. He has published several book chapters and scientific papers, and has regularly presented his work at national meetings. He co-chairs the breast cancer disease site for the American College of Radiation Oncology (ACRO) Accreditation Program. As co-chair, he establishes guidelines for appropriate treatment and care of breast cancer patients, and supervises the review of radiation oncology centers nationwide seeking ACRO accreditation. Furthermore, he continues to be active in research in the areas of breast cancer, stereotactic radiosurgery/radiotherapy and new technologies. He strives to improve treatment outcomes in regards to both achieving higher cure rates but also in minimizing normal tissue side effects.

Dr. Hepel is a member of the American Society of Therapeutic Radiology and Oncology (ASTRO), the American College of Radiation Oncology (ACRO), the American Society of Clinical Oncology (ASCO), the American Brachytherapy Society (ABS), and Association for Directors of Radiation Oncology Programs (ADROP).

Brown Affiliations

scholarly work

Hepel JT and Wazer DE. JCO Grand Rounds: Local management of women over the age of 70 with early stage breast cancer. Journal of Clinical Oncology 2013, in press.

Jaroslaw T. Hepel, MD and Timothy J. Kinsella. "Perez and Brady's Principles and Practice of Radiation Oncology, 6th edition." Chapter 82: Osteosarcoma and Other Primary Tumors of Bone. Lippincott, Williams, and Wilkins, Philadelphia, 2013. In press.

Robert D. Legare, MD, Jaroslaw T. Hepel, MD, and Jennifer S. Gass, MD. "Principles and Practice of Gynecologic Oncology 6th Edition." Chapter: Breast Cancer. Lippincott, Williams, and Wilkins, Philadelphia, 2013. In press.

P Rava, KL Leonard, S Sioshansi, B Curran, DE Wazer, R Cosgrove, G Noren, and JT Hepel. Survival among Patients with Greater than 10 Brain Metastases Treated with Stereotactic Radiosurgery. J Neurosurg. 2013, in press.

Leonard KL, Hepel JT, Hiatt JR, Dipetrillo TA, Price LL, Wazer DE. The Effect of Dose-Volume Parameters and Interfraction Interval on Cosmetic Outcome and Toxicity After 3-Dimensional Conformal Accelerated Partial Breast Irradiation. Int J Radiat Oncol Biol Phys. 2013; 85(3):623-9.

Hepel, JT and Wazer, DE. A Comparison of Brachytherapy Techniques for Partial Breast Irradiation. Brachytherapy, 2012;11(3):163-75.

Hepel JT, Peter J, Hiatt JR, Patel S, Osibanjo O, Safran H, Curran B and DiPetrillo T. Dosimetric feasibility of dose escalation using SBRT boost for stage III non-small cell lung cancer. Front. Oncol. 2012; 2:124.

Hepel JT, Hiatt JR, Cardarelli GA, and Wazer DE. Modeling Study for Optimization of Skin Dose for Partial Breast Irradiation Using Xoft Axxent Electronic Brachytherapy Applicator. Brachytherapy 2010; 9(1):81-5.

David E. Wazer, MD and Jaroslaw T. Hepel, MD. "Accelerated Partial Breast Irradiation, 2nd edition." Chapter 22: Normal Tissue Toxicity after Accelerated Partial Breast Irradiation. Springer, New York, 2009.

Jaroslaw T. Hepel, MD, Shirin Sioshansi, MD, Mark Rivard, PhD, and David E. Wazer, MD. "Accelerated Partial Breast Irradiation, 2nd edition." Chapter 24: New Technologies, Part II: Novel sources and delivery systems. Springer, New York, 2009.

Hepel JT, Evans SB, Hiatt JR, Price LL, DiPetrillo T, Wazer DE, and MacAusland SG. Planning the Breast Boost: A Comparison of Three Techniques and Evolution of the Tumor Bed During Treatment. Int J Rad Onc Bio Phy, 2009; 74(2):458-463.

Hepel JT, Tokita M, MacAusland SG, Evans SB, Hiatt JR, Price LL, DiPetrillo T, Wazer DE. Toxicity of Three-Dimensional Conformal Radiotherapy for Accelerated Partial Breast Irradiation. Int J Rad Onc Bio Phy, 2009; 75(5):1290-1296.

MacAusland SG, Hepel JT, Chong FK, Galper SL, Gass JS, Ruthazer R, Wazer DE. An Attempt to Independently Verify the Utility of the Van Nuys Prognostic Index for Ductal Carcinoma In Situ. Cancer, 2007; 110(12):2648-53.

research statement

Dr. Hepel has particular academic focus and research interest in breast cancer, stereotactic radiosurgery, and new technologies.

Dr. Hepel is involved in research in many aspects of breast cancer. He has been active in evaluating established and novel techniques for accelerated partial breast irradiation (APBI), an approach that strives to limit the impact of radiation treatment on the patient by focusing therapy to only the portion of the breast at risk for tumor recurrence. Non-invasive image-guided breast brachytherapy is a novel approach to APBI that is currently being pioneered at Rhode Island Hospital. In addition, he has evaluated risk stratification for ductal carcinoma in situ (DCIS) and ways to optimize planning and delivery of "boost" radiation.

Dr. Hepel also has a keen interest in radiosurgery or pin-point focused, high-dose radiation for multiple body sites. Stereotactic body radiation therapy (SBRT) has been shown to be very effective for early stage lung cancer. Dr. Hepel is evaluating use of SBRT combined with standard chemoradiation for the management of advanced lung cancer in order to try to improve upon the poor outcomes for this difficult to treat disease. He is also evaluating the role of radiosurgery in the treatment of brain metastases. Using both Gamma Knife and Cyberknife systems, he is evaluating clinical and treatment related parameters to optimize outcome for these patients. Furthermore, Dr. Hepel is involved with research pertaining to treatment of spinal tumors. The Cyberknife robotic radiosurgery system is uniquely suited for treatment of tumors involving the spine. Despite the close proximity of these lesions to the spinal cord, radiation can be sculpted to the target tumor and yet spare this sensitive structure.

Lastly, Dr. Hepel holds an interest in research of new technologies. This includes research on electronic brachytherapy, Accuboost, Cyberknife, as well as other promising technologies.

Through his research, Dr. Hepel strives to improve treatment outcomes for cancer patients in regards to both achieving higher likelihood of cure and minimizing normal tissue side effects.

Active Clinical Protocols:

BrUOG 251: Accelerated Partial Breast Irradiation using Non-invasive Image-guided Breast Brachytherapy (NIBB) for Early Stage Breast Cancer: A Toxicity Assessment.

BrUOG 259: Stereotactic Body Radiation for Consolidation after Standard Chemoradiation for Stage III Lung Cancer.

AccuBoost Registry: Clinical outcomes registry for breast cancer patients receiving tumor bed boost using the Accuboost system.